To determine whether EZH2 suppression facilitated anti-tumor NK cell immunity through CCL2 induction, we also treated mice transplanted with shEzh2 KPC1 PDAC tumors with vehicle, T/P, and/ or a mAb targeting CCL2 (2H5). This evidence concerns the gene CCL2 and neoplasm.